Elizabeth A. Mittendorf
Elite in Triple-Negative Breast Cancer

Dr. Elizabeth A. Mittendorf

Surgical Oncology
330 Brookline Avenue, Shapiro 5, 
Boston, MA 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Triple-Negative Breast Cancer
330 Brookline Avenue, Shapiro 5, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elizabeth Mittendorf is a Surgical Oncologist in Boston, Massachusetts. Dr. Mittendorf is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Lymphadenectomy.

Her clinical research consists of co-authoring 354 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Triple-Negative Breast Cancer.

Graduate Institution
Case Western Reserve University School Of Medicine
Residency
Case Western Reserve University Hospitals
Specialties
Surgical Oncology
Licenses
Surgery in TX
Board Certifications
American Board Of Surgery
Fellowships
The University of Texas MD Anderson Cancer Center
Hospital Affiliations
Brigham And Women's Hospital
Brigham And Women's Faulkner Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Surgery
330 Brookline Avenue, Shapiro 5, Boston, MA 02215

Additional Areas of Focus

Dr. Mittendorf has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Mastectomy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Device, Other
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer
Enrollment Status: Completed
Publish Date: September 05, 2025
Intervention Type: Procedure
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Completed
Publish Date: June 05, 2024
Intervention Type: Biological
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Early Phase 1
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Biological, Drug
Study Drugs: NeuVax vaccine, Trastuzumab, GM-CSF
Study Phase: Phase 2
VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast
VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast
Enrollment Status: Completed
Publish Date: December 05, 2023
Intervention Type: Drug, Other, Biological, Procedure
Study Drugs: Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim
Study Phase: Phase 2
A Prospective, Open Label, Post Marketing Study of Magseed and Sentimag in Patients Undergoing Surgical Excision of a Breast Lesion That Requires Preoperative Radiographic Localization
A Prospective, Open Label, Post Marketing Study of Magseed and Sentimag in Patients Undergoing Surgical Excision of a Breast Lesion That Requires Preoperative Radiographic Localization
Enrollment Status: Completed
Publish Date: February 04, 2021
Intervention Type: Device
Study Phase: Not Applicable
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Enrollment Status: Completed
Publish Date: December 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

354 Total Publications

Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial.
Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial.
Journal: Future oncology (London, England)
Published: October 08, 2025
Similar Doctors
Experienced in Triple-Negative Breast Cancer
Dr. Katherina Z. Calvillo
Surgical Oncology
Experienced in Triple-Negative Breast Cancer
Dr. Katherina Z. Calvillo
Surgical Oncology
44 Binney St., Mayer 1b34, Bwh/dfci Breast Oncology Center, 
Boston, MA 
 (0.1 miles away)
617-632-2174
Languages Spoken:
English
See accepted insurances

Katherina Calvillo is a Surgical Oncologist in Boston, Massachusetts. Dr. Calvillo is rated as an Advanced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Lymphadenectomy.

Experienced in Triple-Negative Breast Cancer
Dr. Micaela A. Weaver
Surgical Oncology | General Surgery
Experienced in Triple-Negative Breast Cancer
Dr. Micaela A. Weaver
Surgical Oncology | General Surgery

Affinity Physicians Llc.

455 Toll Gate Rd, 
Warwick, RI 
 (47.5 miles away)
401-737-7010
Languages Spoken:
English
See accepted insurances

Micaela Weaver is a Surgical Oncologist and a General Surgeon in Warwick, Rhode Island. Dr. Weaver is rated as an Advanced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Paget Disease of the Breast, Intraductal Papilloma, Breast Cancer, HER-2 Positive Breast Cancer, and Salpingo-Oophorectomy.

Experienced in Triple-Negative Breast Cancer
Dr. Michelle C. Specht
General Surgery | Surgical Oncology
Experienced in Triple-Negative Breast Cancer
Dr. Michelle C. Specht
General Surgery | Surgical Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michelle Specht is a General Surgeon and a Surgical Oncologist in Boston, Massachusetts. Dr. Specht is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, Mastectomy, and Lymphadenectomy. Dr. Specht is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mittendorf's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile